Investors in Molina Healthcare Explore Class Action Lawsuit

Investors who acquired shares in **Molina Healthcare, Inc.** (NYSE: MOH) between **February 5, 2025**, and **July 23, 2025**, are being urged to consider joining a class action lawsuit against the company. The law firm **Robbins Geller Rudman & Dowd LLP** has announced that potential lead plaintiffs must submit their applications by **December 2, 2025**.

The lawsuit, titled **Hindlemann v. Molina Healthcare, Inc.**, claims that both the company and its top executives violated the **Securities Exchange Act of 1934**. Key allegations include failing to disclose crucial information regarding Molina’s financial health, particularly concerning its “medical cost trend assumptions.”

According to the lawsuit, investors were not informed about significant issues, such as the disparity between premium rates and medical costs, which the company was experiencing. Furthermore, it is alleged that Molina’s anticipated growth relied heavily on reduced utilization of various health services. As a result, the company’s financial guidance for the fiscal year 2025 was likely to be revised downward.

On **July 7, 2025**, Molina Healthcare reported adjusted earnings of approximately **$5.50 per share**, which fell short of previous expectations due to increased medical costs across all business sectors. The company acknowledged ongoing medical cost pressures that were expected to continue into the latter half of the year. This announcement led to a decline in Molina’s stock price.

Then, on **July 23, 2025**, Molina released its second-quarter financial results for the period ending **June 30, 2025**. The report included a further reduction in the company’s full-year earnings guidance. Molina revealed that its **GAAP net income** was **$4.75 per diluted share**, an **8% decrease year-over-year**, and that it anticipated adjusted earnings of no less than **$19.00 per diluted share** for the full year. This news also resulted in a nearly **17% drop** in Molina’s stock price.

The **Private Securities Litigation Reform Act of 1995** allows any investor who purchased Molina securities during the specified class period to apply for the lead plaintiff role in the lawsuit. The lead plaintiff will represent all members of the class and can appoint a law firm of their choice to oversee the case. Importantly, an investor’s eligibility for any potential future recovery does not depend on their role as lead plaintiff.

**Robbins Geller Rudman & Dowd LLP** is recognized as a leading law firm in securities fraud and shareholder litigation. The firm has achieved significant recoveries for investors, having recovered over **$2.5 billion** in 2024 alone. The firm’s attorneys have been involved in some of the largest securities class action recoveries in history, including a notable **$7.2 billion** recovery in the **Enron Corporation** case.

For more information regarding the class action and to submit an application, interested parties can visit the law firm’s website or contact attorneys J.C. Sanchez or Jennifer N. Caringal directly via phone or email.